A stent delivery assembly comprises a balloon catheter with a rotatable assembly disposed thereabout. The rotatable assembly comprises a rotatable sheath which in a reduced state is freely rotatable about the medical balloon and when in the expanded state is frictionally engaged by the expanded ball
A stent delivery assembly comprises a balloon catheter with a rotatable assembly disposed thereabout. The rotatable assembly comprises a rotatable sheath which in a reduced state is freely rotatable about the medical balloon and when in the expanded state is frictionally engaged by the expanded balloon. A secondary guide wire housing is at least partially engaged to the rotatable sheath. A stent may be disposed about at least a portion of the rotatable sheath and at least a portion of the secondary guide wire housing so that a distal end portion of the secondary guide wire housing exits the flow path of the stent through one of the plurality of cell openings which the stent defines.
대표청구항▼
The invention claimed is: 1. A catheter assembly comprising: a catheter, the catheter comprising a catheter shaft, the catheter shaft defining a first guide wire lumen for passage of a first guide wire therethrough; a rotatable sheath, the rotatable sheath extending around an exterior of at least a
The invention claimed is: 1. A catheter assembly comprising: a catheter, the catheter comprising a catheter shaft, the catheter shaft defining a first guide wire lumen for passage of a first guide wire therethrough; a rotatable sheath, the rotatable sheath extending around an exterior of at least a portion of the catheter shaft and rotatable relative to the catheter shaft at a position radially outward from the catheter shaft, the rotatable sheath having a length substantially less than that of the catheter shaft; a secondary guide wire housing, the secondary guide wire housing defining a secondary guide wire lumen for passage of a secondary guide wire therethrough, at least a first distal portion of the guide wire housing in contact with at least a first proximal portion of the rotatable sheath; and a stent, the stent being expandable from a reduced stent state to an expanded stent state, and defining a flow path between a proximal end opening and a distal end opening, the stent being at least partially constructed from a plurality of interconnected stent members that define a plurality of cell openings therebetween, each of the cell openings being in fluid communication with the flow path, in the reduced stent state the stent is positioned radially outward from and extends around an exterior of at least a portion of the rotatable sheath and at least a portion of the secondary guide wire housing, a distal end portion of the secondary guide wire housing exiting the flow path of the stent through one of the plurality of cell openings. 2. The assembly of claim 1 wherein the stent is selected from at least one member of the group consisting of: a self-expanding stent, a balloon-expandable stent, a hybrid expandable stent and any combination thereof. 3. The assembly of claim 1 wherein at least a portion of the stent is coated with at least one therapeutic agent. 4. The assembly of claim 3 wherein the at least one therapeutic agent is at least one non-genetic therapeutic agent selected from at least one member of the group consisting of: anti-thrombogenic agents; anti-proliferative agents; anti-inflammatory agents; antineoplastic agents; anti-miotic agents; anesthetic agents; anti-coagulants; vascular cell growth promoters; vascular cell growth inhibitors; bifunctional molecules consisting of an antibody and a cytotoxin; cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogenous vascoactive mechanisms. 5. The assembly of claim 3 wherein the at least one therapeutic agent is at least one genetic therapeutic agent selected from at least one member of the group consisting of: anti-sense DNA and RNA; DNA coding for anti-sense RNA, tRNA or rRNA to replace defective or deficient endogenous molecules; angiogenic factors including growth factors; cell cycle inhibitors including CD inhibitors, thymidine kinase ("TK") and other agents useful for interfering with cell proliferation; at least one of the family of bone morphogenic proteins ("BMP's"); dimeric proteins; and molecules capable of inducing an upstream or downstream effect of a BMP, "hedgehog" proteins, or the DNA's encoding them. 6. The assembly of claim 3 wherein the at least one therapeutic agent comprises at least one polymer coating, the at least one coating selected from at least one member of the group consisting of: polycarboxylic acids; cellulosic polymers, including cellulose acetate and cellulose nitrate; gelatin; polyvinylpyrrolidone; cross-linked polyvinylpyrrolidone; polyanhydrides including maleic anhydride polymers; polyamides; polyvinyl alcohols; copolymers of vinyl monomers including EVA; polyvinyl ethers; polyvinyl aromatics; polyethylene oxides; glycosaminoglycans; polysaccharides; polyesters including polyethylene terephthalate; polyacrylamides; polyethers; polyether sulfone; polycarbonate; polyalkylenes including polypropylene, polyethylene and high molecular weight polyethylene; halogenated polyalkylenes including polytetrafluoroethylene; polyurethanes; polyorthoesters; proteins; polypeptides; silicones; siloxane polymers; polylactic acid; polyglycolic acid; polycaprolactone; polyhydroxybutyrate valerate and blends and copolymers thereof; coatings from polymer dispersions; polycsaccharides; hyaluronic acid; squalene emulsions; polyacrylic acid, a copolymer of polylactic acid and polycaprolactone; medical-grade biodegradable materials; polycaprolactone co butyl acrylate and other co polymers; Poly-L-lactic acid blends with DL-Lactic Acid; Poly(lactic acid-co-glycolic acid); polycaprolactone co PLA; polycaprolactone co butyl acrylate and other copolymers; Tyrosine-Derived Polycarbonates and arylate; poly amino acid; polyphosphazenes; polyiminocarbonates; polydimethyltrimethylcarbonates; biodegradable CA/PO4's; cyanoacrylate; 50/50 DLPLG; polydioxanone; polypropylene fumarate; polydepsipeptides; macromolecules including chitosan and Hydroxylpropylmethylcellulose; surface erodible material; maleic anhydride copolymers; zinc-calcium phosphate; amorphous polyanhydrides; sugar; carbohydrate biodegradable polymers; and polymers dissolvable in bodily fluids; A block copolymers; and B block copolymers. 7. The assembly of claim 5 wherein the at least one therapeutic agent is a growth factor selected from at least one member of the group consisting of: acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor α and β, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α, hepatocyte growth factor and insulin like growth factor. 8. The assembly of claim 5 wherein the at least one therapeutic agent is a bone morphogenic proteins ("BMP's") selected from at least one member of the group consisting of: BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 (Vgr-1), BMP-7 (OP-1), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, and BMP-16. 9. The assembly of claim 5 wherein the at least one therapeutic agent comprises a dimeric protein selected from at least one member of the group consisting of: homodimers and heterodimers. 10. The assembly of claim 6 wherein the at least one therapeutic agent comprises at least one coating from polymer dispersion selected from at least one member of the group consisting of polyurethane dispersions, fibrin, collagen and derivatives thereof. 11. The assembly of claim 6 wherein the at least one therapeutic agent comprises at least one polysaccharide selected from at least one member of the group consisting of: celluloses, starches, dextrans, alginates, and derivatives. 12. The assembly of claim 6 wherein the at least one therapeutic agent comprises a medical-grade biodegradable material selected from at least one member of the group consisting of: PGA-TMC, Tyrosine-Derived Polycarbonates, and arylates. 13. The assembly of claim 4 wherein the at least one therapeutic agent comprises a anti-thrombogenic agent selected from at least one member of the group consisting of: heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone). 14. The assembly of claim 4 wherein the at least one therapeutic agent comprises an anti-proliferative agent selected from at least one member of the group consisting of: enoxaprin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid. 15. The assembly of claim 7 wherein the at least one therapeutic agent comprises an anti-inflammatory agents selected from at least one member of the group consisting of: dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine. 16. The assembly of claim 4 wherein the at least one therapeutic agent comprises an anti-coagulants selected from at least one member of the group consisting of: D-Phe-Pro-Arg chloromethyl keton, an RGD peptide-containing compound, heparin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides. 17. The assembly of claim 4 wherein the at least one therapeutic agent comprises at least one member of the group consisting of: paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, and thymidine kinase inhibitors. 18. The assembly of claim 4 wherein the at least one therapeutic agent comprises an anesthetic agent selected from at least one member of the group consisting of: lidocaine, bupivacaine, and ropivacaine. 19. The assembly of claim 4 wherein the at least one therapeutic agent comprises a vascular cell growth promoters selected from at least one member of the group consisting of: growth factor inhibitors, growth factor receptor antagonists, transcriptional activators, and translational promoters. 20. The assembly of claim 4 wherein the at least one therapeutic agent comprises a vascular cell growth inhibitors selected from at least one member of the group consisting of: growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, and bifunctional molecules consisting of a growth factor and a cytotoxin. 21. A catheter assembly comprising: a catheter, the catheter comprising a catheter shaft, the catheter shaft defining a first guide wire lumen for passage of a first guide wire therethrough; a rotatable sheath, the rotatable sheath being disposed about at least a portion of the catheter shaft and rotatable about and relative to the catheter shaft, the rotatable sheath having a length substantially less than that of the catheter shaft; a secondary guide wire housing, the secondary guide wire housing defining a secondary guide wire lumen for passage of a secondary guide wire therethrough, at least a first distal portion of the guide wire housing being engaged to at least a first proximal portion of the rotatable sheath; and a stent, the stent being expandable from a reduced stent state to an expanded stent state, and defining a flow path between a proximal end opening and a distal end opening, the stent being at least partially constructed from a plurality of interconnected stent members that define a plurality of cell openings therebetween, each of the cell openings being in fluid communication with the flow path, in the reduced stent state the stent is disposed about at least a portion of the rotatable sheath and at least a portion of the secondary guide wire housing, a distal end portion of the secondary guide wire housing exiting the flow path of the stent through one of the plurality of cell openings, at least a portion of the stent is coated with at least one therapeutic agent, the at least one therapeutic agent is at least one type of cellular material selected from at least one member of the group consisting of: autologous cells of human origin; allogeneic cells of human origin; and xenogeneic cells of non-human origin. 22. The assembly of claim 21 wherein the cellular material is selected from at least one member of the group consisting of: side population cells; lineage negative cells; lineage negative CD34- cells; lineage negative CD34+ cells; lineage negative -cKit+ cells; mesenchymal stem cells; cord blood bells; tissue derived stem cells; whole bone marrow; bone marrow mononuclear cells; endothelial progenitor cells; satellite cells; muscle derived cells; go cells; endothelial cells; adult cardiomyocytes; fibroblasts; smooth muscle cells; cultures of mesenchymal stem cells with 5-aza forces differentiation into cardiomyocytes; adult cardiac fibroblasts +5-aza; genetically modified cells; tissue engineered grafts; MyoD scar fibroblasts; Pacing cells; embryonic stem cell clones; embryonic stem cells; fetal or neonatal cells; immunologically masked cells; tissue engineered grafts; genetically modified cells; and teratoma derived cells. 23. The assembly of claim 22 wherein the wherein the cellular material includes tissue derived stem cells including cardiac derived stem cells. 24. A catheter assembly comprising: a catheter, the catheter comprising a catheter shaft, the catheter shaft defining a first guide wire lumen for passage of a first guide wire therethrough; a rotatable sheath, the rotatable sheath being disposed about at least a portion of the catheter shaft and rotatable about the catheter shaft, the rotatable sheath having a length substantially less than that of the catheter shaft and being rotatably disposed about at least a portion of a medical balloon; a secondary guide wire housing, the secondary guide wire housing defining a secondary guide wire lumen for passage of a secondary guide wire therethrough, at least a first distal portion of the guide wire housing being engaged to at least a first proximal portion of the rotatable sheath; the medical balloon fixedly mounted to the catheter shaft, the medical balloon expandable from a reduced configuration to an expanded configuration, the catheter shaft further defining an inflation lumen, the inflation lumen being in fluid communication with the medical balloon; and a rotatable collar, the rotatable collar rotatably disposed about a portion of the catheter shaft proximal of the medical balloon, at least a first proximal portion of the secondary guide wire housing being engaged to at least a portion of the rotatable collar. 25. The assembly of claim 24 wherein the rotatable collar defines a catheter shaft lumen therethrough, the catheter shaft being positioned with in the catheter shaft lumen, the catheter shaft lumen having a diameter greater than an outer diameter of the catheter shaft.
Jay A. Lenker ; Kirsten Freislinger ; Michael A. Evans ; Gwendolyn A. Watanabe ; Timothy J. Ryan ; Christopher K. Zarins ; Richard O. Murphy, Apparatus and methods for placement and repositioning of intraluminal prostheses.
Parodi Juan C. (Mercedes 4255 Buenos Aires ARX 1419) Barone Hector D. (Maza 1869/73 Buenos Aires ARX 1240), Balloon device for implanting an aortic intraluminal prosthesis for repairing aneurysms.
Hanson Scott M. ; Traxler Richard J. ; Ellis Louis G. ; Cornelius Linda Lorentzen ; Holman Thomas J. ; Olson Gregory K., Catheter with removable balloon protector.
Hanson Scott M. ; Traxler Richard J. ; Ellis Louis G. ; Cornelius Linda Lorentzen ; Holman Thomas J. ; Olson Gregory K., Catheter with removable balloon protector and stent delivery system with removable stent protector.
Holman Thomas J. ; Ellis Louis G. ; Olson Gregory K. ; Lorentzen Cornelius Linda R. ; Traxler Richard J. ; Hanson Scott M. ; Eidenschink Tracee E. J. ; Williams Sonja J. K., Catheter with removable balloon protector and stent delivery system with removable stent protector.
Thomas J. Holman ; Louis G. Ellis ; Gregory K. Olson ; Linda R. Lorentzen Cornelius ; Richard J. Traxler ; Scott M. Hanson ; Tracee E. J. Eidenschink ; Sonja J. K. Williams, Catheter with removable balloon protector and stent delivery system with removable stent protector.
Payne Sam G. ; Kesten Randy J. ; Aita Michael ; Kume Stewart ; Pearce Stephen B. ; Javier ; Jr. Manuel A. ; Rosenthal Michael H., Delivery catheter system for heart chamber.
Colombo, Antonio; Lashinski, Robert D.; Birdsall, Matthew J.; Brooks, Dennis L.; Haarstad, Philip J.; Peacock, III, James C., Endolumenal prosthesis and method of use in bifurcation regions of body lumens.
Kawula Paul J. (Sunnyvale CA) Beitelia Ray R. (San Jose CA) vander Burg Erik J. (Mountain View CA) Williams Michael S. (Cupertino CA), Fixed-wire dilatation catheter with rotatable balloon assembly.
Dehdashtian Mark ; Saravia Maria Lilian ; Sakata Misuzu, Folding of catheter-mounted balloons to facilitate non-rotational radial expansion of intraluminal devices.
Imran Mir A. ; Hillsman Cecily M. ; Ghandi Deepak R. ; Brooks Dennis L., Low profile balloon-on-a-wire catheter with shapeable and/or deflectable tip and method.
Kaplan Aaron V. (Los Altos CA) Kermode James R. (Sunnyvale CA) Klein Enrique J. (Los Altos CA), Method and apparatus for sequentially performing multiple intraluminal procedures.
Waksman Ron (Atlanta GA) Weldon Thomas D. (Gainesville GA) Hillstead Richard A. (Duluth GA) Rosen Jonathan J. (Alpharetta GA) Larsen Charles E. (Cumming GA) Crocker Ian R. (Stone Mtn. GA) Meloul Raph, Method and apparatus for treating a desired area in the vascular system of a patient.
Goicoechea George (Freeport BSX) Hudson John (Clearwater FL) Mialhe Claude (Draguignan FRX), Method for delivering a bifurcated endoluminal prosthesis.
Fischell Robert E. (14600 Viburnum Dr. Dayton MD 21036) Fischell David R. (71 Riverlawn Dr. Fair Haven NJ 07704) Fischell Tim A. (1018 Chancery Dr. Nashville TN 37215), Multi-cell stent with cells having differing characteristics.
LeVeen Harry H. (321 Confederate Cir. Charleston SC 29407) LeVeen Eric G. (3-3 Woodlake Rd. Albany NY 12203) LeVeen Robert F. (312 Lombard St. Philadelphia PA 19147), Reinforced balloon catheter.
Lau Lilip ; Maroney Charles Thomas ; Hartigan William M. ; Rhee Woonza ; McCullough Kimberly A., Self-expandable helical intravascular stent and stent-graft.
Fearnot Neal E. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees ; III William D. (West Lafayette IN), Thrombolytic treated intravascular medical device.
Chew, Sunmi; Andreas, Bernard; Gifford, III, Hanson S.; French, Ron; Deem, Mark E.; Will, Allan, Apparatus and methods for delivery of multiple distributed stents.
Chew, Sunmi; Andreas, Bernard; Gifford, III, Hanson S.; French, Ron; Deem, Mark E.; Will, Allan, Apparatus and methods for delivery of variable length stents.
Andreas, Bernard; Karratt, Joseph; Flom, James R.; Blackwood, Bradley, Devices and methods for controlling and indicating the length of an interventional element.
Andreas, Bernard; Karratt, Joseph; Flom, James R.; Blackwood, Bradley, Devices and methods for controlling and indicating the length of an interventional element.
Hossainy, Syed F. A.; Trollsas, Mikael O.; Kleiner, Lothar W., Implantable drug delivery devices having alternating hydrophilic and amphiphilic polymer layers.
Hossainy, Syed F. A.; Trollsas, Mikael O.; Kleiner, Lothar W., Implantable drug delivery devices having alternating hydrophilic and amphiphillic polymer layers.
Hanson, Cass A.; Cao, Hong; Chen, John Jianhua; Sutermeister, Derek C.; Quillin, Daniel T.; Pederson, Jr., Gary J., Medical devices for renal nerve ablation.
Kao, Stephen; Andreas, Bernard; Gifford, III, Hanson S.; Deem, Mark E.; Snow, David W.; Grainger, Jeffry J., Multiple independent nested stent structures and methods for their preparation and deployment.
Kao, Stephen; Andreas, Bernard; Gifford, III, Hanson S.; Deem, Mark E.; Snow, David W.; Grainger, Jeffry J., Multiple independent nested stent structures and methods for their preparation and deployment.
Anderson, James M.; Sutermeister, Derek C.; Quillin, Daniel T.; Hanson, Cass A.; Royer, Adam J.; Jancaric, Thomas P.; Lindquist, Jeffrey S., Radio frequency (RF) balloon catheter having flushing and cooling capability.
Haverkost, Patrick A.; Groff, Joel N.; Willard, Martin R.; Ostroot, Timothy A.; Sutermeister, Derek C.; Hanson, Cass A.; Quillin, Daniel T.; Munsinger, Joel R., Renal denervation balloon catheter with ride along electrode support.
Horn, Daniel J.; Squire, Robert N.; Royer, Adam Joseph; Lindquist, Jeffrey S.; Chen, John J., Renal nerve modulation balloon and methods of making and using the same.
Burkart, Dustin C.; Cully, Edward H.; Duncan, Jeffrey B.; Hartman, Cody L.; Silverman, James D., Stent having adjacent elements connected by flexible webs.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.